Key result
Switching from nivolumab to avelumab resolves cardiac lymphoma for over 3 years in a case report.
Why the study?
Cardiac involvement by cutaneous T-cell lymphoma is exceedingly rare and poses diagnostic and therapeutic challenges, with immune checkpoint inhibitors showing variable activity and paradoxical progression.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
This case highlights a potential therapeutic distinction between PD-1 and PD-L1 inhibition, showing that avelumab can resolve nivolumab-associated paradoxical myocardial infiltration of cutaneous T-cell lymphoma.
Cardiac involvement by cutaneous T-cell lymphoma is exceedingly rare and poses considerable diagnostic and therapeutic challenges. Immune checkpoint inhibitors targeting programmed cell death-1 have reported variable activity in T-cell lymphomas and have been associated with paradoxical progression in select cases. We report a 72-year-old man with longstanding indolent CD8-positive cutaneous T-cell lymphoma and metastatic renal cell carcinoma who developed myocardial infiltration by lymphoma after prolonged nivolumab therapy. Diagnosis was established by surgical cardiac biopsy reporting CD3-positive, CD8-positive, and CD30-negative T-cell lymphoma with clonal overlap with prior cutaneous disease. Given concern for paradoxical progression, therapy was transitioned to avelumab, an antiprogrammed death ligand-1 antibody. After nivolumab discontinuation and transition to avelumab, the patient experienced complete metabolic resolution of cardiac involvement, improvement in cardiac biomarkers, and durable control of cutaneous lymphoma over more than 3 years of follow-up. This case highlights a temporal association between programmed cell death-1 blockade and atypical dissemination of cutaneous T-cell lymphoma, supported by biologic plausibility, and underscores a potential therapeutic distinction between programmed cell death-1 and programmed death ligand-1 inhibition in malignant T-cell disorders.
No takes yet. Share an insight, caveat, or question.
Ibrahim et al. (2026) conducted a case report in Cutaneous T-cell lymphoma and metastatic renal cell carcinoma (n=1). Nivolumab followed by avelumab was evaluated on Metabolic resolution of cardiac involvement and control of cutaneous lymphoma. Transitioning from nivolumab to avelumab resulted in complete metabolic resolution of cardiac lymphoma involvement and durable control of cutaneous lymphoma over more than 3 years of follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: